Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers.
Biomed J
; 47(4): 100729, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38657859
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) diagnosis is still the diagnosis of exclusion. Differentiating from other forms of interstitial lung diseases (ILDs) is essential, given the various therapeutic approaches. The IPF course is now unpredictable for individual patients, although some genetic factors and several biomarkers have already been associated with various IPF prognoses. Since its early stages, IPF may be asymptomatic, leading to a delayed diagnosis. The present review critically examines the recent literature on molecular biomarkers potentially useful in IPF diagnostics. The examined biomarkers are grouped into breath and sputum biomarkers, serologically assessed extracellular matrix neoepitope markers, and oxidative stress biomarkers in lung tissue. Fibroblasts and complete blood count have also gained recent interest in that respect. Although several biomarker candidates have been profiled, there has yet to be a single biomarker that proved specific to the IPF disease. Nevertheless, various IPF biomarkers have been used in preclinical and clinical trials to verify their predictive and monitoring potential.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Biomarcadores
/
Fibrosis Pulmonar Idiopática
Límite:
Humans
Idioma:
En
Revista:
Biomed J
Año:
2024
Tipo del documento:
Article
País de afiliación:
Polonia
Pais de publicación:
Estados Unidos